Skip to main content
Erschienen in: Inflammation 6/2013

01.12.2013

Serum Soluble Triggering Receptor on Myeloid Cells-1 (sTREM-1) is Elevated in Systemic Lupus Erythematosus but does not Distinguish Between Lupus Alone and Concurrent Infection

verfasst von: Yair Molad, Elisheva Pokroy-Shapira, Tania Kaptzan, Assaf Monselise, Michal Shalita-Chesner, Yehudit Monselise

Erschienen in: Inflammation | Ausgabe 6/2013

Einloggen, um Zugang zu erhalten

Abstract

We sought to determine serum triggering receptor expressed on myeloid cell-1 (sTREM-1) level in a cohort of patients with systemic lupus erythematosus (SLE). Serum sTREM-1 level of 98 patients with SLE and 49 healthy controls was assayed by ELISA. Serum sTREM-1 level was significantly elevated in a cohort of 78 unselected consecutively recruited patients with SLE (mean 1.1 ± 2.8 ρg/ml, median 0.02 ρg/ml) compared to that of the controls (mean 0.11 ± 0.3 ρg/ml, median 0 ρg/ml; p < 0.0001). We also determined serum sTREM-1 level of 20 SLE patients with a concurrent infection (mean 0.6 ± 1.1 ρg/ml, median 0.12 ρg/ml) and found it not statistically significant compared with that of the patients without infection. Serum sTREM-1 level did not correlate with SLE disease activity. Our finding of elevated serum sTREM-1 level suggests an increased shedding of TREM-1 in SLE and a possible novel pathway of innate immune response in autoimmunity.
Literatur
1.
Zurück zum Zitat Waldner, H. 2009. The role of innate immune responses in autoimmune disease development. Autoimmunity Reviews 8: 400–404.PubMedCrossRef Waldner, H. 2009. The role of innate immune responses in autoimmune disease development. Autoimmunity Reviews 8: 400–404.PubMedCrossRef
2.
Zurück zum Zitat Tsokos, G.C. 2011. Systemic lupus erythematosus. The New England Journal of Medicine 365: 2110–2121.PubMedCrossRef Tsokos, G.C. 2011. Systemic lupus erythematosus. The New England Journal of Medicine 365: 2110–2121.PubMedCrossRef
3.
Zurück zum Zitat Akira, S., S. Uematsu, and O. Takeuchi. 2006. Pathogen recognition and innate immunity. Cell 124(4): 783–801.PubMedCrossRef Akira, S., S. Uematsu, and O. Takeuchi. 2006. Pathogen recognition and innate immunity. Cell 124(4): 783–801.PubMedCrossRef
4.
Zurück zum Zitat Rhee, J.W., K.W. Lee, W.J. Sohn, Y. Lee, O.H. Jeon, H.J. Kwon, and D.S. Kim. 2007. Regulation of matrix metalloproteinase-9 gene expression and cell migration by NF-kappa B in response to CpG-oligodeoxynucleotides in RAW 264.7 cells. Molecular Immunology 44(6): 1393–1400.PubMedCrossRef Rhee, J.W., K.W. Lee, W.J. Sohn, Y. Lee, O.H. Jeon, H.J. Kwon, and D.S. Kim. 2007. Regulation of matrix metalloproteinase-9 gene expression and cell migration by NF-kappa B in response to CpG-oligodeoxynucleotides in RAW 264.7 cells. Molecular Immunology 44(6): 1393–1400.PubMedCrossRef
5.
Zurück zum Zitat Christensen, S.R., M. Kashgarian, L. Alexopoulou, R.A. Flavell, S. Akira, and M.J. Shlomchik. 2005. Toll-like receptor 9 controls anti-DNA autoantibody production in murine lupus. The Journal of Experimental Medicine 202: 321–331.PubMedCrossRef Christensen, S.R., M. Kashgarian, L. Alexopoulou, R.A. Flavell, S. Akira, and M.J. Shlomchik. 2005. Toll-like receptor 9 controls anti-DNA autoantibody production in murine lupus. The Journal of Experimental Medicine 202: 321–331.PubMedCrossRef
6.
Zurück zum Zitat Christensen, S.R., J. Shupe, K. Nickerson, M. Kashgarian, R.A. Flavell, and M.J. Shlomchik. 2006. Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus. Immunity 25: 417–428.PubMedCrossRef Christensen, S.R., J. Shupe, K. Nickerson, M. Kashgarian, R.A. Flavell, and M.J. Shlomchik. 2006. Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus. Immunity 25: 417–428.PubMedCrossRef
7.
Zurück zum Zitat Sato, Y., M. Miyata, T. Nishimaki, H. Kochi, and R. Kasukawa. 1999. CpG motif-containing DNA fragments from sera of patients with systemic lupus erythematosus proliferate mononuclear cells in vitro. Journal of Rheumatology 26: 294–301.PubMed Sato, Y., M. Miyata, T. Nishimaki, H. Kochi, and R. Kasukawa. 1999. CpG motif-containing DNA fragments from sera of patients with systemic lupus erythematosus proliferate mononuclear cells in vitro. Journal of Rheumatology 26: 294–301.PubMed
8.
Zurück zum Zitat Richez, C., P. Blanco, I. Rifkin, J.F. Moreau, and T. Schaeverbeke. 2011. Role for toll-like receptors in autoimmune disease: the example of systemic lupus erythematosus. Joint, Bone, Spine 78: 124–130.PubMedCrossRef Richez, C., P. Blanco, I. Rifkin, J.F. Moreau, and T. Schaeverbeke. 2011. Role for toll-like receptors in autoimmune disease: the example of systemic lupus erythematosus. Joint, Bone, Spine 78: 124–130.PubMedCrossRef
9.
Zurück zum Zitat Barrat, F.J., T. Meeker, J.H. Chan, C. Guiducci, and R.L. Coffman. 2007. Treatment of lupus-prone mice with a dual inhibitor of TLR7 and TLR9 leads to reduction of autoantibody production and amelioration of disease symptoms. European Journal of Immunology 37: 3582–3586.PubMedCrossRef Barrat, F.J., T. Meeker, J.H. Chan, C. Guiducci, and R.L. Coffman. 2007. Treatment of lupus-prone mice with a dual inhibitor of TLR7 and TLR9 leads to reduction of autoantibody production and amelioration of disease symptoms. European Journal of Immunology 37: 3582–3586.PubMedCrossRef
10.
Zurück zum Zitat Tao, K., M. Fujii, S. Tsukumo, Y. Maekawa, K. Kishihara, Y. Kimoto, et al. 2007. Genetic variations of toll-like receptor 9 predispose to systemic lupus erythematosus in Japanese population. Annals of the Rheumatic Diseases 66: 905–909.PubMedCrossRef Tao, K., M. Fujii, S. Tsukumo, Y. Maekawa, K. Kishihara, Y. Kimoto, et al. 2007. Genetic variations of toll-like receptor 9 predispose to systemic lupus erythematosus in Japanese population. Annals of the Rheumatic Diseases 66: 905–909.PubMedCrossRef
11.
Zurück zum Zitat Wu, O., G.P. Chen, H. Chen, X.P. Li, J.H. Xu, S.S. Zhao, et al. 2009. The expressions of toll-like receptor 9 and T-bet in circulating B and T cells in newly diagnosed, untreated systemic lupus erythematosus and correlations with disease activity and laboratory data in a Chinese population. Immunobiology 214: 392–402.PubMedCrossRef Wu, O., G.P. Chen, H. Chen, X.P. Li, J.H. Xu, S.S. Zhao, et al. 2009. The expressions of toll-like receptor 9 and T-bet in circulating B and T cells in newly diagnosed, untreated systemic lupus erythematosus and correlations with disease activity and laboratory data in a Chinese population. Immunobiology 214: 392–402.PubMedCrossRef
12.
Zurück zum Zitat Bouchon, A., J. Dietrich, and M. Colonna. 2000. Cutting edge: inflammatory responses can be triggered by TREM-1, a novel receptor expressed on neutrophils and monocytes. Journal of Immunology 164: 4991–4995. Bouchon, A., J. Dietrich, and M. Colonna. 2000. Cutting edge: inflammatory responses can be triggered by TREM-1, a novel receptor expressed on neutrophils and monocytes. Journal of Immunology 164: 4991–4995.
13.
Zurück zum Zitat Klesney-Tait, J., I.R. Turnbull, and M. Colonna. 2006. The TREM receptor family and signal integration. Nature Immunology 7: 1266–1273.PubMedCrossRef Klesney-Tait, J., I.R. Turnbull, and M. Colonna. 2006. The TREM receptor family and signal integration. Nature Immunology 7: 1266–1273.PubMedCrossRef
14.
Zurück zum Zitat Sharif, O., and S. Knapp. 2008. From expression to signaling: roles of TREM-1 and TREM-2 in innate immunity and bacterial infection. Immunobiology 213(9–10): 701–713.PubMedCrossRef Sharif, O., and S. Knapp. 2008. From expression to signaling: roles of TREM-1 and TREM-2 in innate immunity and bacterial infection. Immunobiology 213(9–10): 701–713.PubMedCrossRef
15.
Zurück zum Zitat Bouchon, A., F. Facchetti, M.A. Weigand, and M. Colonna. 2001. TREM-1 amplifies inflammation and is a crucial mediator of septic shock. Nature 410: 1103–1107.PubMedCrossRef Bouchon, A., F. Facchetti, M.A. Weigand, and M. Colonna. 2001. TREM-1 amplifies inflammation and is a crucial mediator of septic shock. Nature 410: 1103–1107.PubMedCrossRef
16.
Zurück zum Zitat Gibot, S., F. Massin, P. Le Renard, et al. 2005. Surface and soluble triggering receptor expressed on myeloid cells-1: expression patterns in murine sepsis. Critical Care Medicine 33: 1787–1793.PubMedCrossRef Gibot, S., F. Massin, P. Le Renard, et al. 2005. Surface and soluble triggering receptor expressed on myeloid cells-1: expression patterns in murine sepsis. Critical Care Medicine 33: 1787–1793.PubMedCrossRef
17.
Zurück zum Zitat Gibot, S., C. Buonsanti, F. Massin, M. Romano, M.N. Kolopp-Sarda, F. Benigni, G.C. Faure, M.C. Béné, P. Panina-Bordignon, N. Passini, and B. Lévy. 2006. Modulation of the triggering receptor expressed on the myeloid cell type 1 pathway in murine septic shock. Infection and Immunity 74(5): 2823–2830.PubMedCrossRef Gibot, S., C. Buonsanti, F. Massin, M. Romano, M.N. Kolopp-Sarda, F. Benigni, G.C. Faure, M.C. Béné, P. Panina-Bordignon, N. Passini, and B. Lévy. 2006. Modulation of the triggering receptor expressed on the myeloid cell type 1 pathway in murine septic shock. Infection and Immunity 74(5): 2823–2830.PubMedCrossRef
18.
Zurück zum Zitat Kuai, J., B. Gregory, A. Hill, D.D. Pittman, J.L. Feldman, T. Brown, B. Carito, M. O'Toole, R. Ramsey, O. Adolfsson, K.M. Shields, K. Dower, J.P. Hall, Y. Kurdi, J.T. Beech, J. Nanchahal, M. Feldmann, B.M. Foxwell, F.M. Brennan, D.G. Winkler, and L.L. Lin. 2009. TREM-1 expression is increased in the synovium of rheumatoid arthritis patients and induces the expression of pro-inflammatory cytokines. Rheumatology (Oxford, England) 48(11): 1352–1358.CrossRef Kuai, J., B. Gregory, A. Hill, D.D. Pittman, J.L. Feldman, T. Brown, B. Carito, M. O'Toole, R. Ramsey, O. Adolfsson, K.M. Shields, K. Dower, J.P. Hall, Y. Kurdi, J.T. Beech, J. Nanchahal, M. Feldmann, B.M. Foxwell, F.M. Brennan, D.G. Winkler, and L.L. Lin. 2009. TREM-1 expression is increased in the synovium of rheumatoid arthritis patients and induces the expression of pro-inflammatory cytokines. Rheumatology (Oxford, England) 48(11): 1352–1358.CrossRef
19.
Zurück zum Zitat Murakami, Y., T. Akahoshi, N. Aoki, M. Toyomoto, N. Miyasaka, and H. Kohsaka. 2009. Intervention of an inflammation amplifier, triggering receptor expressed on myeloid cells 1, for treatment of autoimmune arthritis. Arthritis and Rheumatism 60(6): 1615–1623.PubMedCrossRef Murakami, Y., T. Akahoshi, N. Aoki, M. Toyomoto, N. Miyasaka, and H. Kohsaka. 2009. Intervention of an inflammation amplifier, triggering receptor expressed on myeloid cells 1, for treatment of autoimmune arthritis. Arthritis and Rheumatism 60(6): 1615–1623.PubMedCrossRef
20.
Zurück zum Zitat Molad Y, Pokroy-Shapira E, Carmon V. CpG-oligodeoxynucleotide-induced TLR9 activation regulates macrophage TREM-1 expression and shedding. Innate Immun. 2013. doi:10.1177/1753425913476970. Molad Y, Pokroy-Shapira E, Carmon V. CpG-oligodeoxynucleotide-induced TLR9 activation regulates macrophage TREM-1 expression and shedding. Innate Immun. 2013. doi:10.​1177/​1753425913476970​.
21.
Zurück zum Zitat Tan, E.M., A.S. Cohen, J.F. Fries, et al. 1982. The 1982 revised criteria for classification of systemic lupus erythematosus. Arthritis and Rheumatism 25: 1271–1277.PubMedCrossRef Tan, E.M., A.S. Cohen, J.F. Fries, et al. 1982. The 1982 revised criteria for classification of systemic lupus erythematosus. Arthritis and Rheumatism 25: 1271–1277.PubMedCrossRef
22.
Zurück zum Zitat Bombardier, C., D. Gladman, M.B. Urowitz, D. Caron, C.H. Chang, and the Committee on Prognosis Studies in SLE. 1992. Derivation of the SLEDAI: a disease activity index for lupus patients. Arthritis and Rheumatism 35: 630–640.PubMedCrossRef Bombardier, C., D. Gladman, M.B. Urowitz, D. Caron, C.H. Chang, and the Committee on Prognosis Studies in SLE. 1992. Derivation of the SLEDAI: a disease activity index for lupus patients. Arthritis and Rheumatism 35: 630–640.PubMedCrossRef
23.
Zurück zum Zitat Gibot, S., M.N. Kolopp-Sarda, M.C. Bene, A. Cravoisy, B. Levy, G.C. Faure, and P.E. Bollaert. 2004. Plasma level of a triggering receptor expressed on myeloid cells-1: its diagnostic accuracy in patients with suspected sepsis. Annals of Internal Medicine 141(1): 9–15.PubMedCrossRef Gibot, S., M.N. Kolopp-Sarda, M.C. Bene, A. Cravoisy, B. Levy, G.C. Faure, and P.E. Bollaert. 2004. Plasma level of a triggering receptor expressed on myeloid cells-1: its diagnostic accuracy in patients with suspected sepsis. Annals of Internal Medicine 141(1): 9–15.PubMedCrossRef
24.
Zurück zum Zitat Gibot, S., A. Cravoisy, B. Levy, M.C. Bene, G. Faure, and P.E. Bollaert. 2004. Soluble triggering receptor expressed on myeloid cells and the diagnosis of pneumonia. The New England Journal of Medicine 350(5): 451–458.PubMedCrossRef Gibot, S., A. Cravoisy, B. Levy, M.C. Bene, G. Faure, and P.E. Bollaert. 2004. Soluble triggering receptor expressed on myeloid cells and the diagnosis of pneumonia. The New England Journal of Medicine 350(5): 451–458.PubMedCrossRef
25.
Zurück zum Zitat Determann, R.M., M. Weisfelt, J. de Gans, A. van der Ende, M.J. Schultz, and D. van de Beek. 2006. Soluble triggering receptor expressed on myeloid cells 1: a biomarker for bacterial meningitis. Intensive Care Medicine 32(8): 1243–1247.PubMedCrossRef Determann, R.M., M. Weisfelt, J. de Gans, A. van der Ende, M.J. Schultz, and D. van de Beek. 2006. Soluble triggering receptor expressed on myeloid cells 1: a biomarker for bacterial meningitis. Intensive Care Medicine 32(8): 1243–1247.PubMedCrossRef
26.
Zurück zum Zitat Bishara, J., N. Hadari, M. Shalita-Chesner, Z. Samra, O. Ofir, M. Paul, N. Peled, S. Pitlik, and Y. Molad. 2007. Soluble triggering receptor expressed on myeloid cells-1 for distinguishing bacterial from aseptic meningitis in adults. European Journal of Clinical Microbiology and Infectious Diseases 26(9): 647–650.PubMedCrossRef Bishara, J., N. Hadari, M. Shalita-Chesner, Z. Samra, O. Ofir, M. Paul, N. Peled, S. Pitlik, and Y. Molad. 2007. Soluble triggering receptor expressed on myeloid cells-1 for distinguishing bacterial from aseptic meningitis in adults. European Journal of Clinical Microbiology and Infectious Diseases 26(9): 647–650.PubMedCrossRef
27.
Zurück zum Zitat Determann, R.M., J.W. van Till, O. van Ruler, S.Q. van Veen, M.J. Schultz, and M.A. Boermeester. 2009. sTREM-1 is a potential useful biomarker for exclusion of ongoing infection in patients with secondary peritonitis. Cytokine 46(1): 36–42.PubMedCrossRef Determann, R.M., J.W. van Till, O. van Ruler, S.Q. van Veen, M.J. Schultz, and M.A. Boermeester. 2009. sTREM-1 is a potential useful biomarker for exclusion of ongoing infection in patients with secondary peritonitis. Cytokine 46(1): 36–42.PubMedCrossRef
28.
Zurück zum Zitat Gibot, S., A. Cravoisy, M.N. Kolopp-Sarda, M.C. Bene, G. Faure, P.E. Bollaert, and B. Levy. 2005. Time-course of sTREM (soluble triggering receptor expressed on myeloid cells)-1, procalcitonin, and C-reactive protein plasma concentrations during sepsis. Critical Care Medicine 33(4): 792–796.PubMedCrossRef Gibot, S., A. Cravoisy, M.N. Kolopp-Sarda, M.C. Bene, G. Faure, P.E. Bollaert, and B. Levy. 2005. Time-course of sTREM (soluble triggering receptor expressed on myeloid cells)-1, procalcitonin, and C-reactive protein plasma concentrations during sepsis. Critical Care Medicine 33(4): 792–796.PubMedCrossRef
29.
Zurück zum Zitat Su, L.X., L. Feng, J. Zhang, Y.J. Xiao, Y.H. Jia, P. Yan, D. Feng, and L.X. Xie. 2011. Diagnostic value of urine sTREM-1 for sepsis and relevant acute kidney injuries: a prospective study. Critical Care 15(5): R250.PubMedCrossRef Su, L.X., L. Feng, J. Zhang, Y.J. Xiao, Y.H. Jia, P. Yan, D. Feng, and L.X. Xie. 2011. Diagnostic value of urine sTREM-1 for sepsis and relevant acute kidney injuries: a prospective study. Critical Care 15(5): R250.PubMedCrossRef
30.
Zurück zum Zitat Zhang, J., D. She, D. Feng, Y. Jia, and L. Xie. 2011. Dynamic changes of serum soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) reflect sepsis severity and can predict prognosis: a prospective study. BMC Infectious Diseases 11: 53.PubMedCrossRef Zhang, J., D. She, D. Feng, Y. Jia, and L. Xie. 2011. Dynamic changes of serum soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) reflect sepsis severity and can predict prognosis: a prospective study. BMC Infectious Diseases 11: 53.PubMedCrossRef
31.
Zurück zum Zitat Collins, C.E., D.T. La, H.T. Yang, F. Massin, S. Gibot, G. Faure, and W. Stohl. 2009. Elevated synovial expression of triggering receptor expressed on myeloid cells 1in patients with septic arthritis or rheumatoid arthritis. Annals of the Rheumatic Diseases 68(11): 1768–1774.PubMedCrossRef Collins, C.E., D.T. La, H.T. Yang, F. Massin, S. Gibot, G. Faure, and W. Stohl. 2009. Elevated synovial expression of triggering receptor expressed on myeloid cells 1in patients with septic arthritis or rheumatoid arthritis. Annals of the Rheumatic Diseases 68(11): 1768–1774.PubMedCrossRef
32.
Zurück zum Zitat Saurer, L., S. Rihs, M. Birrer, N. Saxer-Seculic, M. Radsak, C. Mueller, et al. 2012. Elevated levels of serum-soluble triggering receptor expressed on myeloid cells-1in patients with IBD do not correlate with intestinal TREM-1 mRNA expression and endoscopic disease activity. Journal of Crohn's & Colitis 6(9): 913–923.CrossRef Saurer, L., S. Rihs, M. Birrer, N. Saxer-Seculic, M. Radsak, C. Mueller, et al. 2012. Elevated levels of serum-soluble triggering receptor expressed on myeloid cells-1in patients with IBD do not correlate with intestinal TREM-1 mRNA expression and endoscopic disease activity. Journal of Crohn's & Colitis 6(9): 913–923.CrossRef
33.
Zurück zum Zitat Kim, J., J.K. Koh, E.Y. Lee, J.A. Park, H.A. Kim, E.B. Lee, C. Garlanda, A. Cotena, and Y.W. Song. 2009. Serum levels of soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) and pentraxin 3 (PTX3) as markers of infection in febrile patients with systemic lupus erythematosus. Clinical and Experimental Rheumatology 27: 773–778.PubMed Kim, J., J.K. Koh, E.Y. Lee, J.A. Park, H.A. Kim, E.B. Lee, C. Garlanda, A. Cotena, and Y.W. Song. 2009. Serum levels of soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) and pentraxin 3 (PTX3) as markers of infection in febrile patients with systemic lupus erythematosus. Clinical and Experimental Rheumatology 27: 773–778.PubMed
34.
Zurück zum Zitat Means, T.K., E. Latz, F. Hayashi, M.R. Murali, D.T. Golenbock, and A.D. Luster. 2005. Human lupus autoantibody-DNA complexes activate DCs through cooperation of CD32 and TLR9. The Journal of Clinical Investigation 115: 407–417.PubMed Means, T.K., E. Latz, F. Hayashi, M.R. Murali, D.T. Golenbock, and A.D. Luster. 2005. Human lupus autoantibody-DNA complexes activate DCs through cooperation of CD32 and TLR9. The Journal of Clinical Investigation 115: 407–417.PubMed
35.
Zurück zum Zitat Papadimitraki, E.D., C. Choulaki, E. Koutala, G. Bertsias, C. Tsatsanis, I. Gergianaki, et al. 2006. Expansion of toll-like receptor 9-expressing B cells in active systemic lupus erythematosus: implications for the induction and maintenance of the autoimmune process. Arthritis and Rheumatism 54: 3601–3611.PubMedCrossRef Papadimitraki, E.D., C. Choulaki, E. Koutala, G. Bertsias, C. Tsatsanis, I. Gergianaki, et al. 2006. Expansion of toll-like receptor 9-expressing B cells in active systemic lupus erythematosus: implications for the induction and maintenance of the autoimmune process. Arthritis and Rheumatism 54: 3601–3611.PubMedCrossRef
Metadaten
Titel
Serum Soluble Triggering Receptor on Myeloid Cells-1 (sTREM-1) is Elevated in Systemic Lupus Erythematosus but does not Distinguish Between Lupus Alone and Concurrent Infection
verfasst von
Yair Molad
Elisheva Pokroy-Shapira
Tania Kaptzan
Assaf Monselise
Michal Shalita-Chesner
Yehudit Monselise
Publikationsdatum
01.12.2013
Verlag
Springer US
Erschienen in
Inflammation / Ausgabe 6/2013
Print ISSN: 0360-3997
Elektronische ISSN: 1573-2576
DOI
https://doi.org/10.1007/s10753-013-9694-z

Weitere Artikel der Ausgabe 6/2013

Inflammation 6/2013 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Positiver FIT: Die Ursache liegt nicht immer im Dickdarm

27.05.2024 Blut im Stuhl Nachrichten

Immunchemischer Stuhltest positiv, Koloskopie negativ – in solchen Fällen kann die Blutungsquelle auch weiter proximal sitzen. Ein Forschungsteam hat nachgesehen, wie häufig und in welchen Lokalisationen das der Fall ist.

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

24.05.2024 Diabetische Retinopathie Nachrichten

Möglicherweise hängt es von der Art der Diabetesmedikamente ab, wie hoch das Risiko der Betroffenen ist, dass sich sehkraftgefährdende Komplikationen verschlimmern.

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.